Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery

BACKGROUND: The ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying small-molecule-immunotherapy combinations to increas...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Immunother Cancer
Auteurs principaux: Taylor, Molly A., Hughes, Adina M., Walton, Josephine, Coenen-Stass, Anna M. L., Magiera, Lukasz, Mooney, Lorraine, Bell, Sigourney, Staniszewska, Anna D., Sandin, Linda C., Barry, Simon T., Watkins, Amanda, Carnevalli, Larissa S., Hardaker, Elizabeth L.
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2019
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6883640/
https://ncbi.nlm.nih.gov/pubmed/31779705
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0794-7
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires